GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » 12-1 Month Momentum %

GlaxoSmithKline Pakistan (KAR:GLAXO) 12-1 Month Momentum % : 316.76% (As of Apr. 29, 2025)


View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-04-29), GlaxoSmithKline Pakistan's 12-1 Month Momentum % is 316.76%.

The industry rank for GlaxoSmithKline Pakistan's 12-1 Month Momentum % or its related term are showing as below:

KAR:GLAXO's 12-1 Month Momentum % is ranked better than
99.52% of 1040 companies
in the Drug Manufacturers industry
Industry Median: -5.83 vs KAR:GLAXO: 316.76

Competitive Comparison of GlaxoSmithKline Pakistan's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's 12-1 Month Momentum % falls into.


;
;

GlaxoSmithKline Pakistan  (KAR:GLAXO) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Pakistan  (KAR:GLAXO) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


GlaxoSmithKline Pakistan 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pakistan Business Description

Traded in Other Exchanges
N/A
Address
35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines